C Diff Molecular

C Diff Molecular

1791 bookmarks
Custom sorting
Toxins | Free Full-Text | Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel Syndrome | HTML
Toxins | Free Full-Text | Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel Syndrome | HTML
As a common functional gastrointestinal disorder, irritable bowel syndrome (IBS) significantly affects personal health and imposes a substantial economic burden on society, but the current understanding of its occurrence and treatment is still inadequate. Emerging evidence suggests that IBS is associated with gut microbial dysbiosis, but most studies focus on the bacteria and neglect other communities of the microbiota, including fungi, viruses, archaea, and other parasitic microorganisms. This review summarizes the latest findings that link the nonbacterial microbiota with IBS. IBS patients show less fungal and viral diversity but some alterations in mycobiome, virome, and archaeome, such as an increased abundance of Candida albicans. Moreover, fungi and methanogens can aid in diagnosis. Fungi are related to distinct IBS symptoms and induce immune responses, intestinal barrier disruption, and visceral hypersensitivity via specific receptors, cells, and metabolites. Novel therapeutic methods for IBS include fungicides, inhibitors targeting fungal pathogenic pathways, probiotic fungi, prebiotics, and fecal microbiota transplantation. Additionally, viruses, methanogens, and parasitic microorganisms are also involved in the pathophysiology and treatment. Therefore, the gut nonbacterial microbiota is involved in the pathogenesis of IBS, which provides a novel perspective on the noninvasive diagnosis and precise treatment of this disease.
·mdpi.com·
Toxins | Free Full-Text | Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel Syndrome | HTML
Investigation of metabolic crosstalk between host and pathogenic Clostridioides difficile via multiomics approaches - PubMed
Investigation of metabolic crosstalk between host and pathogenic Clostridioides difficile via multiomics approaches - PubMed
Clostridioides difficile is a gram-positive anaerobic bacterium that causes antibiotic-associated infections in the gut. C. difficile infection develops in the intestine of a host with an imbalance of the intestinal microbiota and, in severe cases, can lead to toxic megacolon, intestin …
·pubmed.ncbi.nlm.nih.gov·
Investigation of metabolic crosstalk between host and pathogenic Clostridioides difficile via multiomics approaches - PubMed
GutMicrobiota Health on Twitter
GutMicrobiota Health on Twitter
We're happy to organize together with @esnm_eu this new webinar on the management of recurrence of Clostridioides difficile infection.🗣 Daniel Pohl, Steven Johnson & Tariq Iqbal.👉 Join us on 12th October: https://t.co/r1Bf5MuTOk pic.twitter.com/Wzx1RrZX4T— GutMicrobiota Health (@GMFHx) September 15, 2022
·twitter.com·
GutMicrobiota Health on Twitter
Antibiotic resistance and genomic features of Clostridioides difficile in southwest China - PubMed
Antibiotic resistance and genomic features of Clostridioides difficile in southwest China - PubMed
Most of the C. difficile isolates in this study were resistant to macrolide and aminoglycoside antibiotics. Moreover, the MDR strains were commonly found. All the isolates belonged to clade 1 and clade 4 according to phylogenetic analysis of bacterial genome, and highly genomic diversity of c …
·pubmed.ncbi.nlm.nih.gov·
Antibiotic resistance and genomic features of Clostridioides difficile in southwest China - PubMed
Clostridiumnovyi's Alpha-Toxin Changes Proteome and Phosphoproteome of HEp-2 Cells
Clostridiumnovyi's Alpha-Toxin Changes Proteome and Phosphoproteome of HEp-2 Cells
C. novyi type A produces the alpha-toxin (TcnA) that belongs to the large clostridial glucosylating toxins (LCGTs) and is able to modify small GTPases by N-acetylglucosamination on conserved threonine residues. In contrast, other LCGTs including Clostridioides difficile toxin A and tox …
·pubmed.ncbi.nlm.nih.gov·
Clostridiumnovyi's Alpha-Toxin Changes Proteome and Phosphoproteome of HEp-2 Cells
Comparison of the Risk of Recurrent Clostridioides Difficile Infections Among Patients in 2018 Versus 2013 - PubMed
Comparison of the Risk of Recurrent Clostridioides Difficile Infections Among Patients in 2018 Versus 2013 - PubMed
Among persons with an initial Clostridioides difficile infection (CDI) across 10 US sites in 2018 compared with 2013, 18.3% versus 21.1% had ≥1 recurrent CDI (rCDI) within 180 days. We observed a 16% lower adjusted risk of rCDI in 2018 versus 2013 (P .0001).
·pubmed.ncbi.nlm.nih.gov·
Comparison of the Risk of Recurrent Clostridioides Difficile Infections Among Patients in 2018 Versus 2013 - PubMed
Role of Pannexin-1-P2X7R signaling on cell death and pro-inflammatory mediator expression induced by Clostridioides difficile toxins in enteric glia - PubMed
Role of Pannexin-1-P2X7R signaling on cell death and pro-inflammatory mediator expression induced by Clostridioides difficile toxins in enteric glia - PubMed
Clostridioides difficile (C. difficile) produces toxins A (TcdA) and B (TcdB), both associated with intestinal damage and diarrhea. Pannexin-1 (Panx1) channels allows the passage of messenger molecules, such as adenosine triphosphate (ATP), which in turn activate the P2X7 receptors (P2 …
·pubmed.ncbi.nlm.nih.gov·
Role of Pannexin-1-P2X7R signaling on cell death and pro-inflammatory mediator expression induced by Clostridioides difficile toxins in enteric glia - PubMed
Impact of Clostridioides difficile infection in patients admitted with ulcerative colitis - PubMed
Impact of Clostridioides difficile infection in patients admitted with ulcerative colitis - PubMed
CDI is a prevalent situation in hospitalised UC patients related to higher mortality within the first 3 months after the infection, need for therapy intensification within the first year and readmission. Our results underline the importance of CDI detection in patients with a flare of UC.
·pubmed.ncbi.nlm.nih.gov·
Impact of Clostridioides difficile infection in patients admitted with ulcerative colitis - PubMed
HUMAN FECAL BILE ACID ANALYSIS AFTER INVESTIGATIONAL MICROBIOTA-BASED LIVE BIOTHERAPEUTIC DELIVERY FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION | medRxiv
HUMAN FECAL BILE ACID ANALYSIS AFTER INVESTIGATIONAL MICROBIOTA-BASED LIVE BIOTHERAPEUTIC DELIVERY FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION | medRxiv
Intestinal microbiome disruption is associated with recurrent Clostridioides difficile infection (rCDI), which poses a high risk of morbidity and mortality. Microbiome-based therapeutics are increasingly evaluated as a strategy to reduce rCDI, and their proposed mechanisms include restoration of the microbiota and microbiota-mediated functions, including bile acid (BA) metabolism. This study reports the development of a highly quantitative and sensitive assay for targeted metabolomic assessment of bile acids, and the application of the assay to profile bile acid composition in a Phase 2 trial of the investigational microbiota-based live biotherapeutic RBX2660 for reduction of rCDI (PUNCH CD2; [NCT02299570][1]). Participants were asked to provide stool samples before and up to 24 months after treatment. A liquid chromatography tandem mass spectrometry method was developed to extract and quantify 35 BAs from a total of 113 participant stool samples from 27 rCDI participants treated with RBX2660 in the double-blinded, placebo-controlled clinical trial. The results demonstrate a high-confidence assay as represented by sensitivity, linearity, accuracy, and precision of the output measurements of BAs. When the assay was utilized to assess stool samples from the clinical trial participants, primary BAs were the dominant BA species at baseline, consistent with the expected loss of commensals after broad-spectrum antibiotic treatment. As early as 7 days after RBX2660 administration, there was a significant drop in primary BAs concurrent with increased secondary BAs, and this profile was sustained through 24 months after RBX2660 administration. Taken together, we describe a robust assay that demonstrates altered BA metabolism associated with RBX2660 administration, shifting towards a profile that is consistent with a healthier BA profile and clinical response. ### Competing Interest Statement RP, NF, KS, and BCF are employees of Ferring Pharmaceuticals. KB is an employee of Rebiotix Inc., a Ferring company. CG and BS are employed by BioRankings, LLC, which received fees for this analysis from Rebiotix Inc., a Ferring company. ### Clinical Trial NCT02299570 ### Funding Statement The work was supported by Rebiotix Inc., a Ferring company, and the Ferring Research Institute of Ferring Pharmaceuticals. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The institutional review board/research ethics board (IRB/REB) at each participating center approved the study protocol and informed consent form (Quorum Review, University of Chicago Biological Sciences Division/University of Chicago Medical Center; Western IRB; Louis Stokes Cleveland Department of Veterans Affairs Medical Center IRB; Henry Ford Health System IRB; University of Pennsylvania Institutional Review Board; St. Vincents Hospital and Health Care Center, Inc IRB; Loyola University Chicago Health Sciences Division Institutional Review Board for the Protection of Human Subjects; Mayo Clinic Institutional Review Boards; Weill Cornell Medical College IRB; IRB of St. Ritas Health Partners; HealthPartners Institute for Education and Research IRB; Hamilton Integrated Research Ethics Board; University of British Columbia Clinical Research Ethics Board; Washington University Human Research Protection Office). All study participants provided written informed consent. An independent medical monitor provided safety oversight. All methods were carried out in accordance with relevant guidelines and regulations. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The datasets presented in this article are not readily available because they are restricted by an ongoing commercialization process. Requests to access the datasets should be directed to KB. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT02299570&atom=%2Fmedrxiv%2Fearly%2F2022%2F09%2F01%2F2022.08.30.22278604.atom
·medrxiv.org·
HUMAN FECAL BILE ACID ANALYSIS AFTER INVESTIGATIONAL MICROBIOTA-BASED LIVE BIOTHERAPEUTIC DELIVERY FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION | medRxiv
GutMicrobiota Health on Twitter
GutMicrobiota Health on Twitter
.@gianluca1aniro: C. difficile infection is a simple model of dysbiosis. The decrease of secondary bile salts due to antibiotic treatment is a major contributor that favours vegetative growth of C. difficile @esnm_eu #GMFHCoverage pic.twitter.com/G6IMSIlVj6— GutMicrobiota Health (@GMFHx) September 6, 2022
·twitter.com·
GutMicrobiota Health on Twitter
A compendium of 32,277 metagenome-assembled genomes and over 80 million genes from the early-life human gut microbiome | Nature Communications
A compendium of 32,277 metagenome-assembled genomes and over 80 million genes from the early-life human gut microbiome | Nature Communications
Nature Communications - Here the authors present a large-scale resource of the early-life human gut microbiome from children under three years old, which comprises 32,277 metagenome-assembled gut...
·nature.com·
A compendium of 32,277 metagenome-assembled genomes and over 80 million genes from the early-life human gut microbiome | Nature Communications
Rounding out cyclic dinucleotide signaling in Clostridioides difficile: A role and a mechanism for c-di-AMP - PubMed
Rounding out cyclic dinucleotide signaling in Clostridioides difficile: A role and a mechanism for c-di-AMP - PubMed
The second messenger c-di-AMP contributes to various homeostatic and stress responses in bacteria. In this issue of Science Signaling, Oberkampf et al. have identified it as a mediator of osmotic stress and bile salt resistance in the opportunistic pathogen Clostridioides difficile …
·pubmed.ncbi.nlm.nih.gov·
Rounding out cyclic dinucleotide signaling in Clostridioides difficile: A role and a mechanism for c-di-AMP - PubMed
VanG- and D-Ala-D-Ser-dependent peptidoglycan synthesis and vancomycin resistance in Clostridioides difficile
VanG- and D-Ala-D-Ser-dependent peptidoglycan synthesis and vancomycin resistance in Clostridioides difficile
A Clostridioides difficile strain deficient in the ddl gene is unable to synthesize the dipeptide D-Ala-D-Ala, an essential component of peptidoglycan and the target of vancomycin. We isolated spontaneous suppressors of a ∆ddl mutation that allowed cell growth in the absence of D-Ala-D-Ala. The muta …
·pubmed.ncbi.nlm.nih.gov·
VanG- and D-Ala-D-Ser-dependent peptidoglycan synthesis and vancomycin resistance in Clostridioides difficile
Impact of environmental conditions and gut microbiota on the in vitro germination and growth of Clostridioides difficile
Impact of environmental conditions and gut microbiota on the in vitro germination and growth of Clostridioides difficile
Clostridioides difficile is a spore-forming anaerobic Gram-positive bacterium responsible for a broad spectrum of intestinal symptoms and healthcare associated diarrhoea. The hypothesis of this work was that different in vitro conditions, notably pH and human faecal microbiota composition impact the …
·pubmed.ncbi.nlm.nih.gov·
Impact of environmental conditions and gut microbiota on the in vitro germination and growth of Clostridioides difficile
Impact of environmental conditions and gut microbiota on the in vitro germination and growth of Clostridioides difficile
Impact of environmental conditions and gut microbiota on the in vitro germination and growth of Clostridioides difficile
Clostridioides difficile is a spore-forming anaerobic Gram-positive bacterium responsible for a broad spectrum of intestinal symptoms and healthcare associated diarrhoea. The hypothesis of this work was that different in vitro conditions, notably pH and human faecal microbiota composition impact the …
·pubmed.ncbi.nlm.nih.gov·
Impact of environmental conditions and gut microbiota on the in vitro germination and growth of Clostridioides difficile
Recognition of extracellular DNA by type IV pili promotes biofilm formation by Clostridioides difficile - PubMed
Recognition of extracellular DNA by type IV pili promotes biofilm formation by Clostridioides difficile - PubMed
Clostridioides difficile is a Gram-positive bacillus, which is a frequent cause of gastrointestinal infections triggered by the depletion of the gut microbiome. Because of the frequent recurrence of these infections after antibiotic treatment, mechanisms of C. difficile persistence and recurrence, i …
·pubmed.ncbi.nlm.nih.gov·
Recognition of extracellular DNA by type IV pili promotes biofilm formation by Clostridioides difficile - PubMed
Plakoglobin and High-Mobility Group Box 1 Mediate Intestinal Epithelial Cell Apoptosis Induced by Clostridioides difficile TcdB - PubMed
Plakoglobin and High-Mobility Group Box 1 Mediate Intestinal Epithelial Cell Apoptosis Induced by Clostridioides difficile TcdB - PubMed
Clostridioides difficile infection (CDI) is the leading cause of antibiotic-associated intestinal disease, resulting in severe diarrhea and fatal pseudomembranous colitis. TcdB, one of the essential virulence factors secreted by this bacterium, induces host cell apoptosis through a poorly understood …
·pubmed.ncbi.nlm.nih.gov·
Plakoglobin and High-Mobility Group Box 1 Mediate Intestinal Epithelial Cell Apoptosis Induced by Clostridioides difficile TcdB - PubMed
Clostridioides difficile toxin is infrequently detected in inflammatory bowel disease and does not associate with clinical outcomes - PubMed
Clostridioides difficile toxin is infrequently detected in inflammatory bowel disease and does not associate with clinical outcomes - PubMed
When compared to those without IBD, patients with IBD have a reduced proportion of cases of C. difficile with toxin positivity. Differences in clinical outcomes among patients with IBD were not detected and limited by the infrequent detection of expressed toxin.
·pubmed.ncbi.nlm.nih.gov·
Clostridioides difficile toxin is infrequently detected in inflammatory bowel disease and does not associate with clinical outcomes - PubMed
Clostridioides difficile TcdB Toxin Glucosylates Rho GTPase by an S Ni Mechanism and Ion Pair Transition State - PubMed
Clostridioides difficile TcdB Toxin Glucosylates Rho GTPase by an S Ni Mechanism and Ion Pair Transition State - PubMed
Toxins TcdA and TcdB from Clostridioides difficile glucosylate human colon Rho GTPases. TcdA and TcdB glucosylation of RhoGTPases results in cytoskeletal changes, causing cell rounding and loss of intestinal integrity. Clostridial toxins TcdA and TcdB are proposed to catalyze glucosylation of …
·pubmed.ncbi.nlm.nih.gov·
Clostridioides difficile TcdB Toxin Glucosylates Rho GTPase by an S Ni Mechanism and Ion Pair Transition State - PubMed
In Silico Characterization of Uncharacterized Proteins From Multiple Strains of Clostridium Difficile
In Silico Characterization of Uncharacterized Proteins From Multiple Strains of Clostridium Difficile
Clostridium difficile (C. difficile) is a multi-strain, spore-forming, Gram-positive, opportunistic enteropathogen bacteria, majorly associated with nosocomial infections, resulting in severe diarrhoea and colon inflammation. Several antibiotics including penicillin, tetracycline, and …
·pubmed.ncbi.nlm.nih.gov·
In Silico Characterization of Uncharacterized Proteins From Multiple Strains of Clostridium Difficile